Nothing Special   »   [go: up one dir, main page]

FR2910896B1 - Anticorps monoclonal dirige contre le recepteur humain des ldl - Google Patents

Anticorps monoclonal dirige contre le recepteur humain des ldl

Info

Publication number
FR2910896B1
FR2910896B1 FR0611546A FR0611546A FR2910896B1 FR 2910896 B1 FR2910896 B1 FR 2910896B1 FR 0611546 A FR0611546 A FR 0611546A FR 0611546 A FR0611546 A FR 0611546A FR 2910896 B1 FR2910896 B1 FR 2910896B1
Authority
FR
France
Prior art keywords
monoclonal antibody
directed against
antibody directed
human receptor
ldl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0611546A
Other languages
English (en)
Other versions
FR2910896A1 (fr
Inventor
Romeuf Christophe De
Christian Behrens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0611546A priority Critical patent/FR2910896B1/fr
Application filed by LFB SA filed Critical LFB SA
Priority to AU2007346741A priority patent/AU2007346741A1/en
Priority to KR1020097013066A priority patent/KR20100014279A/ko
Priority to JP2009543504A priority patent/JP2010514434A/ja
Priority to PCT/FR2007/002187 priority patent/WO2008099071A2/fr
Priority to EP07872460A priority patent/EP2167544A2/fr
Priority to CA002661853A priority patent/CA2661853A1/fr
Priority to US12/519,275 priority patent/US20100098706A1/en
Priority to CN200780048492A priority patent/CN101679524A/zh
Publication of FR2910896A1 publication Critical patent/FR2910896A1/fr
Application granted granted Critical
Publication of FR2910896B1 publication Critical patent/FR2910896B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR0611546A 2006-12-29 2006-12-29 Anticorps monoclonal dirige contre le recepteur humain des ldl Expired - Fee Related FR2910896B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR0611546A FR2910896B1 (fr) 2006-12-29 2006-12-29 Anticorps monoclonal dirige contre le recepteur humain des ldl
KR1020097013066A KR20100014279A (ko) 2006-12-29 2007-12-28 인간 엘디엘 수용체에 대한 단일클론항체
JP2009543504A JP2010514434A (ja) 2006-12-29 2007-12-28 ヒトｌｄｌ受容体に対するモノクローナル抗体
PCT/FR2007/002187 WO2008099071A2 (fr) 2006-12-29 2007-12-28 Anticorps monoclonal dirigé contre le récepteur humain des ldl
AU2007346741A AU2007346741A1 (en) 2006-12-29 2007-12-28 Monoclonal antibody directed against the human LDL receptor
EP07872460A EP2167544A2 (fr) 2006-12-29 2007-12-28 Antocorps monoclonal dirige contre le recepteur humain des ldl
CA002661853A CA2661853A1 (fr) 2006-12-29 2007-12-28 Anticorps monoclonal dirige contre le recepteur humain des ldl
US12/519,275 US20100098706A1 (en) 2006-12-29 2007-12-28 Monoclonal antibody directed against the human ldl receptor
CN200780048492A CN101679524A (zh) 2006-12-29 2007-12-28 针对人类ldl受体的单克隆抗体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0611546A FR2910896B1 (fr) 2006-12-29 2006-12-29 Anticorps monoclonal dirige contre le recepteur humain des ldl

Publications (2)

Publication Number Publication Date
FR2910896A1 FR2910896A1 (fr) 2008-07-04
FR2910896B1 true FR2910896B1 (fr) 2012-11-16

Family

ID=38229736

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0611546A Expired - Fee Related FR2910896B1 (fr) 2006-12-29 2006-12-29 Anticorps monoclonal dirige contre le recepteur humain des ldl

Country Status (9)

Country Link
US (1) US20100098706A1 (fr)
EP (1) EP2167544A2 (fr)
JP (1) JP2010514434A (fr)
KR (1) KR20100014279A (fr)
CN (1) CN101679524A (fr)
AU (1) AU2007346741A1 (fr)
CA (1) CA2661853A1 (fr)
FR (1) FR2910896B1 (fr)
WO (1) WO2008099071A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9623117B2 (en) * 2011-04-04 2017-04-18 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
WO2014206561A1 (fr) * 2013-06-26 2014-12-31 Numab Ag Structures d'anticorps

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139217A0 (en) * 2000-03-13 2001-11-25 Applied Research Systems Monoclonal antibodies to the human ldl receptor, their production and use
FR2879204B1 (fr) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
FR2889533B1 (fr) * 2005-08-03 2007-10-12 Lab Francais Du Fractionnement Anticorps diriges contre le recepteur du ldl

Also Published As

Publication number Publication date
CA2661853A1 (fr) 2008-08-21
US20100098706A1 (en) 2010-04-22
CN101679524A (zh) 2010-03-24
WO2008099071A3 (fr) 2008-12-18
FR2910896A1 (fr) 2008-07-04
WO2008099071A8 (fr) 2009-10-22
WO2008099071A2 (fr) 2008-08-21
AU2007346741A1 (en) 2008-08-21
KR20100014279A (ko) 2010-02-10
JP2010514434A (ja) 2010-05-06
EP2167544A2 (fr) 2010-03-31

Similar Documents

Publication Publication Date Title
LTC2379594I2 (lt) Žmogaus CGRP receptorių rišantys antikūnai
FR18C1011I2 (fr) Anticorps humains a forte affinite diriges contre le recepteur de l il-4 humaine
HRP20181616T1 (hr) Potpuno ljudska anti-vap-1 monoklonska antitijela
IL200610A0 (en) Human monoclonal anti-ip-10 antibodies and uses thereof
EP2021373A4 (fr) Anticorps monoclonal vcam-1 spécifique
IL216381A0 (en) Antagonistic human light-specific human monoclonal antibodies
DK2069403T3 (da) Human-antistoffer med høj affinitet for human IL-4 receptor
DK3002298T3 (da) Anti-faktor xi monoklonale antistoffer og fremgangsmåder til anvendelse deraf
BRPI0817637A2 (pt) anticorpo anti-glipican-3 tendo cinéticas aperfeiçoadas no plasma
BRPI0814252A2 (pt) Formulações de anticorpo
BRPI0814003A2 (pt) Formulações de anticorpo
HK1121767A1 (zh) 誘導細胞凋亡的抗- 抗體
ATE465169T1 (de) Hemmstoffe des progesteron-rezeptors
BRPI0814111A2 (pt) Anticorpo monoclonal citotóxico anticâncer
FR2889533B1 (fr) Anticorps diriges contre le recepteur du ldl
BRPI0819765A2 (pt) Conjugados de anticorpos anti-rg-1
BRPI0816689A2 (pt) antígenos mutantes gas57 e anticorpos gas57
EP2077325A4 (fr) Anticorps monoclonal et son utilisation
EP2230250A4 (fr) Anticorps monoclonal anti-vih
FR2922212B1 (fr) Anticorps anti ricine
FR2889532B1 (fr) Anticorps diriges contre le recepteur du ldl
FR2910896B1 (fr) Anticorps monoclonal dirige contre le recepteur humain des ldl
BRPI0814116A2 (pt) Anticorpo monoclonal citotóxico anticâncer
BRPI0813520A2 (pt) Anticorpo monoclonal citotóxico anticâncer
ZA200901165B (en) Antagonistic human light-specific human monoclonal antibodies

Legal Events

Date Code Title Description
CJ Change in legal form
TP Transmission of property
ST Notification of lapse

Effective date: 20140829